Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting
ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical ASKB589 at the 2025 ESMO Annual Meeting. The drug, in combination with CAPOX and PD-1 inhibitors, has shown deep and lasting tumor remission and disease control in first-line treatment of advanced gastric cancer, with clear survival benefits. These positive clinical data will enhance the market competitiveness of the company's products
According to the Zhitong Finance APP, Aosaikang (002755.SZ) announced that its subsidiary ASKGENE LIMITED will present the latest research results of the innovative biological drug ASK589 (targeting CLDN18.2 monoclonal antibody) in combination with CAPOX and PD-1 inhibitors for first-line treatment of advanced gastric cancer at the European Society for Medical Oncology (ESMO) annual meeting held in Berlin, Germany on October 19, 2025, in the form of a poster.
The Ib/II clinical study of ASK589 (targeting CLDN18.2 monoclonal antibody) in combination with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitors for first-line treatment of locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma patients continues to show deep and durable tumor responses and disease control with longer follow-up, demonstrating clear survival benefits, supporting the ongoing key clinical III phase study of ASK589 combined with chemotherapy and PD-1 inhibitors.
The data on the ASK589 triple therapy disclosed at the ESMO conference further confirms its significant and lasting anti-tumor activity and reveals for the first time its overall survival (OS) benefits in patients with advanced first-line gastric cancer. The positive clinical data will help enhance the future market competitiveness of the company's products
